poisar

Stocks · News reference

Mesoblast Receives FDA Approval To Implement A New Potency Assay, T-Cell Proliferation Inhibition Bioassay, For Release And Stability Monitoring Of All New Commercial Product Lots Of Its Mesenchymal Stromal Cell Product Ryoncil

BenzingaBenzinga Newsdesk

The TIBA assay will ensure sufficient sensitivity to detect any shifts in potency of the commercial product that could arise during changes in manufacturing processes or production in new facilities. This assay will be

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncMesoblast Limited

    Mesoblast Showcased at ASX Premier Investor Day Event

    Mesoblast Limited presented at the ASX Investor Day in Melbourne, highlighting its transformation into a commercial-stage biotechnology company. The company outlined key value-creation priorities including expansion of its FDA-approved Ryoncil® therapy into adult acute graft-versus-host disease, advancement of rexlemestrocel-L for inflammatory chronic low back pain and cardiopulmonary indications, and disciplined capital deployment for commercial growth and late-stage development programs.

  2. Fiscal.ai

    Mesoblast Highlighted at ASX Investor Day

    Mesoblast Limited participated in the Australian Securities Exchange (ASX) Investor Day in Melbourne, presenting on its transition to a commercial-stage biotechnology company.

  3. Globenewswire IncMesoblast Limited

    Mesoblast Board Changes

    Mesoblast Limited announced board changes with the retirement of William Burns (after 12 years) and Philip Krause (since 2022). The company plans to recruit new directors with U.S. and global commercial expertise as it transitions to a revenue-generating commercial enterprise following the FDA approval and successful U.S. launch of Ryoncil® for pediatric steroid-refractory acute graft versus host disease.